Nonalcoholic fatty liver disease

被引:175
|
作者
Krawczyk, Marcin [2 ]
Bonfrate, Leonilde [1 ]
Portincasa, Piero [1 ]
机构
[1] Univ Bari, Dept Internal Med & Publ Med DIMIMP, Clin Med A Murri, I-70121 Bari, Italy
[2] Saarland Univ Hosp, Dept Med 2, Homburg, Germany
关键词
Fatty acids; Hepatic steatosis; Insulin resistance; Metabolic syndrome; Mitochondrial dysfunction; Visceral adiposity; INCREASED INTESTINAL PERMEABILITY; TOTAL PARENTERAL-NUTRITION; PLACEBO-CONTROLLED TRIAL; OBSTRUCTIVE SLEEP-APNEA; NECROSIS-FACTOR-ALPHA; VITAMIN-E TREATMENT; INSULIN-RESISTANCE; HEPATIC STEATOSIS; OXIDATIVE STRESS; LONG-TERM;
D O I
10.1016/j.bpg.2010.08.005
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Non-alcoholic fatty liver disease (NAFLD) the most common liver disorder in the Western world is a climco-histopathological entity in which excessive triglyceride accumulation in the liver occurs Non-alcoholic steatohepatitis (NASH) represents the necroinflammatory form which can lead to advanced liver fibrosis cirrhosis and hepatocellular carcinoma The pathogenesis of NAFLD/NASH is complex but Increased visceral adiposity plus insulin resistance with increased free fatty acids release play an initial key role for the onset and perpetuation of liver steatosis Further events in the liver include oxidative stress and lipid peroxidation decreased antioxidant defences early mitochondrial dysfunction iron accumulation unbalance of adipose-derived adipokines with a chronic proinflammatory status and gut-derived microbial adducts New gene polymorphisms increasing the risk of fatty liver namely APOC3 and PNPLA3 have been lately identified allowing further insights into the pathogenesis of this condition In our review pathophysiological genetic, and essential diagnostic and therapeutic aspects of NAFLD are examined with future trends in this field highlighted (C) 2010 Elsevier Ltd All rights reserved
引用
收藏
页码:695 / 708
页数:14
相关论文
共 50 条
  • [1] Nonalcoholic Fatty Liver Disease Is Related to Nonalcoholic Fatty Pancreas Disease
    van Geenen, Erwin-Jan M.
    Smits, Mark M.
    Schreuder, Tim C. M. A.
    van der Peet, Donald L.
    Bloemena, Elisabeth
    Mulder, Chris J. J.
    [J]. PANCREAS, 2010, 39 (08) : 1185 - 1190
  • [3] Nonalcoholic fatty liver disease
    Bayard, Max
    Holt, Jim
    Boroughs, Eileen
    [J]. AMERICAN FAMILY PHYSICIAN, 2006, 73 (11) : 1961 - 1968
  • [4] Nonalcoholic fatty liver disease
    Clark, JM
    Brancati, FL
    Diehl, AM
    [J]. GASTROENTEROLOGY, 2002, 122 (06) : 1649 - 1657
  • [5] Nonalcoholic fatty liver disease
    Alfie, ME
    Treem, WR
    [J]. PEDIATRIC ANNALS, 2006, 35 (04): : 290 - +
  • [6] Nonalcoholic Fatty Liver Disease
    Sweet, Patrick H.
    Khoo, Teresa
    Nguyen, Steven
    [J]. PRIMARY CARE, 2017, 44 (04): : 599 - +
  • [7] Nonalcoholic Fatty Liver Disease
    Wang, Xiao Jing
    Malhi, Harmeet
    [J]. ANNALS OF INTERNAL MEDICINE, 2018, 169 (09) : ITC65 - ITC80
  • [8] Nonalcoholic Fatty Liver Disease
    Fitzgerald, Margaret A.
    [J]. NURSE PRACTITIONER, 2007, 32 (02): : 6 - 7
  • [9] Nonalcoholic fatty liver disease
    Elizabeth M. Brunt
    Vincent W.-S. Wong
    Valerio Nobili
    Christopher P. Day
    Silvia Sookoian
    Jacquelyn J. Maher
    Elisabetta Bugianesi
    Claude B. Sirlin
    Brent A. Neuschwander-Tetri
    Mary E. Rinella
    [J]. Nature Reviews Disease Primers, 1
  • [10] Nonalcoholic fatty liver disease
    Madan, P
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 173 (07) : 734 - 735